Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Gilead

'The Handmaid's Tale' Season 6 Review: Hulu's Brutal Dystopian Show Finally Gets An Ending

After eight years of fascist dystopia, June Osborne finally gets to rest.

Inverse

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

MarketBeat

These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

UNAIDS chief urges Donald Trump to make an 'amazing deal' to end HIV

The UNAIDS director also warned that US funding cuts could be dire for global efforts to curb HIV.

Euronews

AIDS pandemic risks 'resurging globally' amid US funding halt: UN

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, the UN's top AIDS official said Monday, warning millions would die.

Radio France Internationale

UNAIDS director proposes that President Trump make an 'amazing deal' to end HIV

The head of the U.N. AIDS agency says the sudden loss of American money has been “devastating” for efforts to stop HIV and will cost many lives of the world’s most vulnerable people

The Independent UK

Gilead Sciences - Leader in HIV Medicines

Summary Gilead Sciences (GILD) shows strong technical buy signals, with a 19.60% gain since Trend Seeker's buy signal on 1/27 and a 50.31% gain in the last year. The company offers a diverse portfolio of medicines for HIV, COVID-19, liver diseases, oncology, and more, with significant collaborations enhancing its pipeline....

Barchart

Read news from The Economist, FT, and more,
with one subscription

How Is Gilead Sciences' Stock Performance Compared to Other Pharmaceutical Stocks?

As Gilead Sciences has outperformed its industry peers recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer

MarketBeat

The Handmaid's Tale season 6: everything we know so far about the hit Hulu show’s return

The Handmaid's Tale season 6 returns to Hulu on April 8 – here's everything we know about the dystopian drama's return.

TechRadar

Stock Index Futures Slip on Trump Tariffs, Powell’s Testimony on Tap

March S&P 500 E-Mini futures (ESH25) are down -0.33%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.44% this morning as investors digested another round of tariffs introduced by U.S. President Donald Trump and looked ahead to Federal Reserve Chair Jerome Powell’s congressional testimony as well as Wednesday’s release…

Barchart

Gilead Sciences Stock: Is Wall Street Bullish or Bearish?

Shares of Gilead Sciences have surpassed the broader market over the past year, and Wall Street analysts are reasonably upbeat about its future outlook.

Barchart

Earnings Preview: What to Expect From Gilead Sciences’ Report

Gilead Sciences is likely to report its fiscal fourth-quarter earnings next month, and analysts are expecting a modest fall in its earnings.

Barchart

3 Biotech Innovators Advancing Genetic Therapies

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

Gilead Sciences has recently demonstrated strong performance, outperforming the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on its future.

Benzinga

Looking At Gilead Sciences's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences (NASDAQ:GILD).

The Independent UK

A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?

A twice-yearly shot that prevents HIV infections will be available at low cost in 120 poor countries

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Fewest New HIV Cases Since Late 1980s: UNAIDS Report

Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations said Tuesday, warning that this decline was still far too slow.

International Business Times

'Remarkable Global Progress': HIV Cases And Deaths Declining

The number of new HIV infections and deaths has fallen across the world, marking significant progress in the fight against the disease.

Barchart

Gilead Sciences Stock: Analyst Estimates & Ratings

Gilead Sciences has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s prospects.

StockNews.com

3 Biotechnology Stocks With Promising Pipelines

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.

Barchart

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

Gilead Sciences’ Quarterly Earnings Preview: What You Need to Know

Gilead Sciences is scheduled to report its fiscal third-quarter earnings next month, and analysts anticipate a lower-double-digit drop in its EPS.

StockNews.com

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.